JP5844355B2 - グルコキナーゼ活性剤としての３−オキソ−３，９−ジヒドロ−１Ｈ−クロメノ［２，３−ｃ］ピロール - Google Patents

グルコキナーゼ活性剤としての３−オキソ−３，９−ジヒドロ−１Ｈ−クロメノ［２，３−ｃ］ピロール Download PDF

Info

Publication number
JP5844355B2
JP5844355B2 JP2013514676A JP2013514676A JP5844355B2 JP 5844355 B2 JP5844355 B2 JP 5844355B2 JP 2013514676 A JP2013514676 A JP 2013514676A JP 2013514676 A JP2013514676 A JP 2013514676A JP 5844355 B2 JP5844355 B2 JP 5844355B2
Authority
JP
Japan
Prior art keywords
dihydro
oxo
chromeno
pyrrol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013514676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013532146A (ja
JP2013532146A5 (enExample
Inventor
サラブ，ラマカンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2013532146A publication Critical patent/JP2013532146A/ja
Publication of JP2013532146A5 publication Critical patent/JP2013532146A5/ja
Application granted granted Critical
Publication of JP5844355B2 publication Critical patent/JP5844355B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2013514676A 2010-06-17 2011-06-14 グルコキナーゼ活性剤としての３−オキソ−３，９−ジヒドロ−１Ｈ−クロメノ［２，３−ｃ］ピロール Expired - Fee Related JP5844355B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35561910P 2010-06-17 2010-06-17
US61/355,619 2010-06-17
PCT/EP2011/059783 WO2011157682A1 (en) 2010-06-17 2011-06-14 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators

Publications (3)

Publication Number Publication Date
JP2013532146A JP2013532146A (ja) 2013-08-15
JP2013532146A5 JP2013532146A5 (enExample) 2014-07-31
JP5844355B2 true JP5844355B2 (ja) 2016-01-13

Family

ID=44266428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013514676A Expired - Fee Related JP5844355B2 (ja) 2010-06-17 2011-06-14 グルコキナーゼ活性剤としての３−オキソ−３，９−ジヒドロ−１Ｈ−クロメノ［２，３−ｃ］ピロール

Country Status (10)

Country Link
US (1) US8178689B2 (enExample)
EP (1) EP2582706A1 (enExample)
JP (1) JP5844355B2 (enExample)
KR (1) KR20130120993A (enExample)
CN (1) CN102947311B (enExample)
BR (1) BR112012032235A2 (enExample)
CA (1) CA2801168A1 (enExample)
MX (1) MX2012010668A (enExample)
RU (1) RU2603191C2 (enExample)
WO (1) WO2011157682A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ709362A (en) * 2012-12-25 2019-07-26 Hua Medicine Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1h-pyrazol-3-ylamine
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
US20210387996A1 (en) * 2018-10-24 2021-12-16 Hoffmann-La Roche Inc. Tricyclic compounds for the treatment and prophylaxis of hepatitis b virus disease
CN113493442B (zh) * 2020-04-03 2024-11-08 天津药物研究院有限公司 作为葡萄糖激酶活化剂的吡咯烷酮衍生物及其制备方法和用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI844083L (fi) 1983-10-18 1985-04-19 Du Pont 8-substituerade pyrazolopentatiepiner och foereningar, som haenfoer sig till dessa.
JPS6284064A (ja) 1985-10-09 1987-04-17 Shionogi & Co Ltd ３−パ−フルオロアルキル−５−ヒドロキシイソオキサゾ−ル類
JPH0477477A (ja) 1990-07-18 1992-03-11 Takeda Chem Ind Ltd チアジアゾール酢酸誘導体の製造法
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
IL103678A (en) 1991-11-13 1996-09-12 Schering Ag History of pyrazolylpyrazole, processes for their preparation and herbicidal preparations containing them
US5498190A (en) 1994-06-27 1996-03-12 Handsontoys, Inc. Flexible foam construction toy and method of manufacturing same
JPH08151386A (ja) 1994-09-27 1996-06-11 Takeda Chem Ind Ltd 複素環エチルチオセフェム化合物、その製造法および抗菌組成物
KR20010043004A (ko) 1998-04-30 2001-05-25 개리 이. 프라이드만 피코르나 바이러스 억제 화합물, 그의 제조 방법 및 용도
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
EP1196411B1 (en) 1999-07-15 2003-09-17 Pharmacopeia, Inc. Bradykinin b1 receptor antagonists
US7329679B2 (en) 2000-01-27 2008-02-12 Schering Aktiengesellschaft 1,2 Diarylbenzimidazoles and their pharmaceutical use
EP1282611B1 (en) 2000-05-08 2004-10-20 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
DE60309856T2 (de) 2002-04-26 2007-06-14 F. Hoffmann-La Roche Ag Substituierte phenylacetamide und deren verwendung als glucokinaseaktivatoren
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
WO2004033462A2 (en) 2002-10-09 2004-04-22 The Board Of Trustees Of The University Of Illinois METHOD OF PREPARING (3R, 3aS, 6aR) -3- HYDROXYHEXAHYDROFURO [2, 3-b] FURAN AND RELATED COMPOUNDS
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7629362B2 (en) 2003-02-13 2009-12-08 Banyu Pharmaceutical Co., Ltd. 2-pyridine carboxamide derivatives
MXPA05009059A (es) 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
KR20070008517A (ko) 2003-10-24 2007-01-17 아벤티스 파마슈티칼스 인크. 카텝신 저해물질로서 신규한 케토-옥사디아졸 유도체
AU2004287416C1 (en) 2003-10-27 2010-09-09 Merck Sharp & Dohme Corp. CCR-2 antagonist salt
PT1723128E (pt) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaril-ureias e o seu uso como activadores da glicoquinase
CA2554686A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Compounds
US20080293722A1 (en) 2004-03-16 2008-11-27 Wyeth Ion Channel Modulators
AU2005223610B2 (en) 2004-03-23 2008-05-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR100672184B1 (ko) * 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
US8148412B2 (en) 2004-12-03 2012-04-03 Novo Nordisk A/S Heteroaromatic glucokinase activators
WO2006064286A1 (en) 2004-12-13 2006-06-22 Medivir Uk Ltd Cathepsin s inhibitors
KR20080024211A (ko) 2005-07-08 2008-03-17 노보 노르디스크 에이/에스 디시클로알킬 우레아 글루코키나제 활성제
AR057661A1 (es) 2005-07-11 2007-12-12 Tanabe Seiyaku Co Un derivado de oxima y sus preparaciones
BRPI0612996A2 (pt) 2005-07-14 2010-12-14 Novo Nordisk As ativadores de urÉia glucocinase
EP1921074A1 (en) 2005-08-31 2008-05-14 Astellas Pharma Inc. Thiazole derivative
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
US8796313B2 (en) 2005-11-01 2014-08-05 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
US20070197532A1 (en) 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
ES2378704T3 (es) 2006-01-27 2012-04-17 Array Biopharma, Inc. Activadores de la glucocinasa
EP2543667B1 (en) 2006-03-24 2015-01-28 Array Biopharma, Inc. A method of preparing 2-aminopyridine analogs as glucokinase activators
WO2007115968A2 (en) 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Process for the preparation of a glucokinase activator
EP2463283B1 (en) 2006-04-20 2014-06-11 Pfizer Products Inc. Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
CA2649577A1 (en) 2006-04-28 2007-11-08 Transtech Pharma, Inc. Benzamide glucokinase activators
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
CN101490064B (zh) * 2006-07-06 2012-10-10 百时美施贵宝公司 新颖葡萄糖激酶活化剂及其使用方法
MX2009000688A (es) 2006-07-24 2009-01-30 Hoffmann La Roche Pirazoles como activadores de glucocinasa.
MX2009009525A (es) 2007-03-07 2009-09-16 Kyorin Seiyaku Kk Activador de glucocinasa.
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators

Also Published As

Publication number Publication date
US20110313002A1 (en) 2011-12-22
JP2013532146A (ja) 2013-08-15
MX2012010668A (es) 2012-10-03
RU2603191C2 (ru) 2016-11-27
US8178689B2 (en) 2012-05-15
CN102947311B (zh) 2015-11-25
CN102947311A (zh) 2013-02-27
RU2012156706A (ru) 2014-07-27
BR112012032235A2 (pt) 2019-09-24
EP2582706A1 (en) 2013-04-24
CA2801168A1 (en) 2011-12-22
KR20130120993A (ko) 2013-11-05
HK1178532A1 (zh) 2013-09-13
WO2011157682A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
JP5518838B2 (ja) ピロリジノングルコキナーゼアクチベーター
JP5301655B2 (ja) ピリダジノングルコキナーゼアクチベーター
EP3187492A1 (en) Pyrimidinone derivative having autotaxin-inhibitory activity
AU2014352008B2 (en) Tricyclic piperidine compounds
JP2013532146A (ja) グルコキナーゼ活性剤としての３−オキソ−３，９−ジヒドロ−１Ｈ−クロメノ［２，３−ｃ］ピロール
US20130131113A1 (en) Pyridone glucokinase activators
HK1178532B (en) 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators
EP2880027B1 (en) N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof
US12565494B2 (en) Inhibitors of human respiratory syncytial virus and metapneumovirus
US20120142705A1 (en) Isatin and oxindole compounds
KR20150064727A (ko) 신규한 페닐아세트아미드 화합물 및 이를 함유하는 의약

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140613

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150305

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151020

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151118

R150 Certificate of patent or registration of utility model

Ref document number: 5844355

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees